Dose escalation for locally advanced pancreatic cancer: How high can we go?-Reference-Cited by-同舟云学术

Dose escalation for locally advanced pancreatic cancer: How high can we go?

Published:2018-10 Issue:4 Volume:3 Page:693-700
ISSN:2452-1094
Container-title:Advances in Radiation Oncology
language:en
Short-container-title:Advances in Radiation Oncology

Author:

Colbert Lauren E.,Rebueno Neal,Moningi Shalini,Beddar Sam,Sawakuchi Gabriel O.,Herman Joseph M.,Koong Albert C.,Das Prajnan,Holliday Emma B.,Koay Eugene J.,Taniguchi Cullen M.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference17 articles.

1. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial;Hammel;JAMA,2016

4. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation;Krishnan;Int J Radiat Oncol Biol Phys,2016

5. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC;Colbert;Adv Radiat Oncol,2017

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol;Clinical and Translational Radiation Oncology;2024-07

2. Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11;Cancers;2023-12-29

3. Pancreatic SABR using peritumoral fiducials, triggered imaging and breath-hold;Pathology and Oncology Research;2023-12-21

4. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial;The Lancet Oncology;2023-12

5. Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer;Radiotherapy and Oncology;2023-11